NCT05993884View on ClinicalTrials.gov

Safety and Preliminary Efficacy of Allogeneic Endothelial Progenitor Cells (EPCs) in Patients With Acute Ischemic Stroke

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

August 24, 2023

Primary Completion Date

April 15, 2025

Study Completion Date

April 15, 2025

Conditions
Acute Ischemic Stroke
Interventions
DRUG

iEPCs

Patients receive iEPCs IV with the single dose

DRUG

Placebo

Patients receive placebo IV with a single dose

Trial Locations (2)

100053

Allife Medicine （Beijing） Limitied, Beijing

Unknown

Allife, Beijing

All Listed Sponsors
collaborator

Linfen Central Hospital

UNKNOWN

collaborator

Peking University Third Hospital

OTHER

collaborator

Xuanwu Hospital, Beijing

OTHER

collaborator

Beijing Tiantan Hospital

OTHER

collaborator

Linyi People's Hospital

OTHER

lead

Allife Medical Science and Technology Co., Ltd.

INDUSTRY